TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31804299

Group type: EXPERIMENTAL
Intervention: Sepsis patients in ICU
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Sepsis patients with severe sepsis
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Sepsis patients with septic shock
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Patients with pneumonia as infection site
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Patients with bloodstream infection as infection site
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Low body weight
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Higher Sequential Organ Failure Assessment score
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Number of systemic inflammatory response syndrome criteria
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Comorbid conditions (heart failure, hematologic cancer, immunosuppression)
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Higher level of lactate
Number of subjects: 2322
Study: 31804669

Group type: EXPERIMENTAL
Intervention: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide single-tablet regimen
Number of subjects: 0
Study: 31804967

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for benign thyroid disease
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for malignant thyroid disease
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy for Graves' disease
Number of subjects: 800

Group type: COMPARATOR
Intervention: Postoperative complications
Number of subjects: 800
Study: 31805015

Group type: EXPERIMENTAL
Intervention: Weight loss (10%) in obese-NAFLD group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Obese-NAFLD group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lean group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall correlation
Number of subjects: 67
Study: 31805182

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 203
Study: 31805424

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Novel biomarkers (soluble ST2, growth differentiation factor-15, Galectin-3)
Number of subjects: 441
Study: 31805921

Group type: EXPERIMENTAL
Intervention: Alfapump system (AP)
Number of subjects: 17
Study: 31805926

Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Medical complications
Number of subjects: 1055
Study: 31806098

Group type: EXPERIMENTAL
Intervention: Total sugars
Number of subjects: 624128

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 624128

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 624128

Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 624128
Study: 31806360

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Moderate depressive symptoms
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Overall depressive symptoms
Number of subjects: 186
Study: 31806397

Group type: EXPERIMENTAL
Intervention: Baseline serum betaine <77.7 μmol/L
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Baseline serum betaine ≥77.7 μmol/L
Number of subjects: 622

Group type: COMPARATOR
Intervention: Serum betaine
Number of subjects: 622
Study: 31806391

Group type: EXPERIMENTAL
Intervention: CTA-derived RESOLVE score
Number of subjects: 363

Group type: COMPARATOR
Intervention: Angiographic V-RESOLVE score
Number of subjects: 363

Group type: COMPARATOR
Intervention: Non-high-risk group (CTA-derived RESOLVE)
Number of subjects: 363

Group type: COMPARATOR
Intervention: High-risk group (CTA-derived RESOLVE)
Number of subjects: 363
Study: 31806403

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study: 31806470

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (diet and physical activity) for 8 weeks
Number of subjects: 41
Study: 31806613

Group type: EXPERIMENTAL
Intervention: Metoprolol optimal dosing pathway
Number of subjects: 1000
Study: 31806722

Group type: EXPERIMENTAL
Intervention: Acute diesel exhaust exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31806930

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 744
Study: 31807036

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) treatment starting from the second trimester (24-27 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) treatment starting from the third trimester (28-30 weeks)
Number of subjects: 129
Study: 31807102

Group type: EXPERIMENTAL
Intervention: Fluvoxamine for 8 weeks
Number of subjects: 31
Study: 31807350

Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation for 4 weeks before meals
Number of subjects: 28

Group type: COMPARATOR
Intervention: Follow-up period without DAO supplementation
Number of subjects: 28
Study: 31807567

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 60
Study: 31808620

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study: 31809241

Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg once daily
Number of subjects: 41
Study: 31809243

Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pertuzumab with neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HER2 blockade (trastuzumab and pertuzumab)
Number of subjects: 40
Study: 31809506

Group type: EXPERIMENTAL
Intervention: Elective cesarean section (CS)
Number of subjects: 97291

Group type: EXPERIMENTAL
Intervention: Nonelective cesarean section (CS)
Number of subjects: 97291

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 97291

Group type: EXPERIMENTAL
Intervention: Any form of cesarean section (elective or nonelective)
Number of subjects: 97291
Study: 31809725

Group type: EXPERIMENTAL
Intervention: Recombinant E1E2 complex vaccine
Number of subjects: 551
Study: 31810059

Group type: EXPERIMENTAL
Intervention: Having network members who exercised
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Having network members who were exercise partners
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Exercise partner being a spouse
Number of subjects: 689
Study: 31810577

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 1-5 mg/kg/day (maximum 200 mg/day) during long-term evaluation
Number of subjects: 149
Study: 31810978

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cholinesterase inhibitor and memantine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation and medical foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-modifying interventions targeting amyloid cascade hypothesis
Number of subjects: 0
Study: 31811016

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 32
Study: 31811481

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 13
Study: 31811550

Group type: EXPERIMENTAL
Intervention: Aortic peak systolic velocity variation (ΔV) monitoring
Number of subjects: 0
Study: 31811682

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATRA-induced autophagy
Number of subjects: 0
Study: 31811953

Group type: EXPERIMENTAL
Intervention: Serum levels of keratin 18 (K18M65 and K18M30)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ratio of K18M65:ALT
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ratio of K18M65:M30
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: K18 levels
Number of subjects: 173
Study: 31812112

Group type: EXPERIMENTAL
Intervention: Low SES infants
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Medium SES infants
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Low SES preschool children
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Medium SES preschool children
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Urban residence
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 2068

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 2068
Study: 31812141

Group type: EXPERIMENTAL
Intervention: Conservative management (CM)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Surgical management (SM)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Endovascular management (EM)
Number of subjects: 581
Study: 31812268

Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique after instructional video; 10 emergency tracheotomies performed on rabbit cadavers.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; first attempt performance.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; learning curve analysis.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Emergency front of neck access (eFONA) technique; comparison of injuries by sex.
Number of subjects: 50
Study: 31812517

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) parameters
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: IVUS minimum lumen area (MLA), plaque burden, OCT-MLA, and OCT-area stenosis
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Anatomical parameters (IVUS or OCT)
Number of subjects: 330
Study: 31812759

Group type: EXPERIMENTAL
Intervention: Fast nicotine metabolizers
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Slow nicotine metabolizers
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Caucasian fast metabolizers
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 121
Study: 31812892

Group type: EXPERIMENTAL
Intervention: WBI + supraclavicular radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WBI + internal mammary irradiation (IMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WBI
Number of subjects: 0
Study: 31813077

Group type: EXPERIMENTAL
Intervention: ART adherence intervention
Number of subjects: 143
Study: 31813280

Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 8468
Study: 31813736

Group type: EXPERIMENTAL
Intervention: Awakening to hospital discharge (T1-T3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ICU to hospital discharge (T2-T3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: At ICU discharge (T2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study: 31813938

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) 55-75 mg/m
Number of subjects: 67
Study: 31814102

Group type: EXPERIMENTAL
Intervention: Integrated care with therapeutic assertive community treatment (IC-TACT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 214
Study: 31814209

Group type: EXPERIMENTAL
Intervention: One-session virtual reality exposure treatment (VRET)
Number of subjects: 204
Study: 31814441

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31814753

Group type: EXPERIMENTAL
Intervention: Oliceridine IV (G-protein selective agonist at the µ-opioid receptor)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Oliceridine IV
Number of subjects: 768
Study: 31814830

Group type: EXPERIMENTAL
Intervention: USPIO-labeled mesenchymal stromal cells (MSCs)
Number of subjects: 5
Study: 31815106

Group type: EXPERIMENTAL
Intervention: Labial group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lingual group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 31803847

Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI) models with malaria-exposed volunteers
Number of subjects: 0
Study: 31815579

Group type: EXPERIMENTAL
Intervention: CTL019 (low-dose cohort)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CTL019 (high-dose single infusion cohort)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CTL019 (high-dose fractionated cohort)
Number of subjects: 35
Study: 31815592

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study: 31815739

Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37 inoculation
Number of subjects: 0
Study: 31816630

Group type: EXPERIMENTAL
Intervention: Risk model for 6-month post-AMI mortality
Number of subjects: 3006

Group type: EXPERIMENTAL
Intervention: Functional impairments (hearing impairment, mobility impairment) included in the risk model
Number of subjects: 3006
Study: 31816924

Group type: EXPERIMENTAL
Intervention: Multimodal intervention for cancer cachexia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 46
Study: 31817776

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 686
Study: 31817795

Group type: EXPERIMENTAL
Intervention: 4G8-SDIE (Fc-optimized FLT3 antibody)
Number of subjects: 0
Study: 31817885

Group type: EXPERIMENTAL
Intervention: Fixed combination of extracts of restharrow root, Java tea, and goldenrod herb (Aqualibra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31818252

Group type: EXPERIMENTAL
Intervention: Audio-visual falls prevention messages
Number of subjects: 38
Study: 31818278

Group type: EXPERIMENTAL
Intervention: IPS e.max press (Ivoclar-Vivadent)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Initial LiSi press (GC Co.)
Number of subjects: 60
Study: 31818281

Group type: EXPERIMENTAL
Intervention: Prolonged grief reaction defined by an ICG (Inventory Complicated Grief) > 25 at 6 months after patient's death.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Anxiety and depression symptoms based on Hospital Anxiety and Depression score > 8 for each subscale between day 3 and day 5 and at 6 months after patient's death.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder symptoms based on the Impact of Events Scale questionnaire score > 22 at 6 months after patient's death.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Experience of relatives during palliative care based on the Fami-Life questionnaire.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Phone interview with relatives with prolonged grief reactions planned between 6 and 12 months after the patient's death.
Number of subjects: 500
Study: 31818317

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 55
Study: 31818338

Group type: EXPERIMENTAL
Intervention: Central venous catheter-related bloodstream infections
Number of subjects: 0
Study: 31818840

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Number of subjects: 5
Study: 31819193

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: In vitro assays with metformin
Number of subjects: 36
Study: 31819352

Group type: EXPERIMENTAL
Intervention: Proparacaine 1%
Number of subjects: 140

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 140
Study: 31819404

Group type: EXPERIMENTAL
Intervention: Nebulized Budesonide (NBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic Corticosteroids (SCS)
Number of subjects: 0
Study: 31819544

Group type: EXPERIMENTAL
Intervention: Cefiderocol, a novel siderophore cephalosporin designed to target CR pathogens.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 31819574

Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education (DSME) intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Comparison group (no DSME intervention)
Number of subjects: 220
Study: 31819619

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Number of subjects: 3980

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 3980
Study: 31819632

Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3D-ASL
Number of subjects: 120

Group type: COMPARATOR
Intervention: IVIM-DWI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DCE-MRI-derived histogram features
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single modal histogram features
Number of subjects: 120
Study: 31819674

Group type: EXPERIMENTAL
Intervention: Intravenous amisulpride, 10 mg dose
Number of subjects: 6
Study: 31820038

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (Matsuda Insulin Sensitivity Index; IS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin production
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Changes in glucose metabolism
Number of subjects: 27
Study: 31820130

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 30
Study: 31820157

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection (LSD)
Number of subjects: 118
Study: 31820199

Group type: EXPERIMENTAL
Intervention: Pemetrexed/Erlotinib (pemetrexed 500 mg/m2)
Number of subjects: 29
Study: 31820214

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) measured at the little finger
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) measured at the index finger
Number of subjects: 49
Study: 31820531

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31820981

Group type: EXPERIMENTAL
Intervention: Covalent inhibitor of KRAS (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific treatment not mentioned)
Number of subjects: 0
Study: 31821172

Group type: EXPERIMENTAL
Intervention: 2 mg d6-α-tocopherol
Number of subjects: 2

Group type: COMPARATOR
Intervention: 5 mg d6-α-tocopherol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fluorescent-labeled α-tocopherol
Number of subjects: 2
Study: 31821335

Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (mean)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (maximal)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Computed tomography reticulation index (minimal)
Number of subjects: 326
Study: 31821339

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 16 weeks, 3 days/week
Number of subjects: 63
Study: 31821456

Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 75 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 300 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 31821530

Group type: EXPERIMENTAL
Intervention: High oral splint
Number of subjects: 21
Study: 31821798

Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training (EGT)
Number of subjects: 10
Study: 31822247

Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by secondary education
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by primary education
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by skilled manual occupation
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Lower cognitive reserve (CR) indicated by nonskilled manual occupation
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Korean version of the Mini-Mental State Examination total score
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Higher education, occupation, or composite CR score
Number of subjects: 7459

Group type: EXPERIMENTAL
Intervention: Korean version of the Mini-Mental State Examination scores in older adults
Number of subjects: 7459
Study: 31822479

Group type: EXPERIMENTAL
Intervention: Advance care planning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31822542

Group type: EXPERIMENTAL
Intervention: Standardised diagnostic and treatment algorithm involving neurologists and cardiologists; transesophageal echocardiogram for patients depending on age strata; implantable cardiac monitor for all patients; PFO closure planned for patients <60 years with PFO and no AF evidence within 6 months after stroke.
Number of subjects: 0
Study: 31822574

Group type: EXPERIMENTAL
Intervention: Elevated Lp-PLA
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Presence of both ICAS and nonelevated Lp-PLA
Number of subjects: 797
Study: 31822684

Group type: EXPERIMENTAL
Intervention: Tenacity (mindfulness video game)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control game
Number of subjects: 0
Study: 31823097

Group type: EXPERIMENTAL
Intervention: Digital PET scanner (dPET, Vereos PET/CT, Philips)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional PET scanner (cPET, Ingenuity TF PET/CT, Philips)
Number of subjects: 50
Study: 31823806

Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 60 mg once per month for three consecutive months
Number of subjects: 328
Study: 31823832

Group type: EXPERIMENTAL
Intervention: Vorinostat, starting dose 180 mg/m², intra-patient dose escalation until maximum tolerated dose (MTD)
Number of subjects: 0
Study: 31824147

Group type: EXPERIMENTAL
Intervention: Baseline inflammatory biomarkers (IL-6, hs-CRP, miR-23a) and pH value in exhaled breath condensate
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Lung spirometry tests
Number of subjects: 10000
Study: 31824318

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31824355

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31824412

Group type: EXPERIMENTAL
Intervention: Intravenous Thrombolysis
Number of subjects: 0
Study: 31824423

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31824943

Group type: EXPERIMENTAL
Intervention: Augmented α1PI blood concentration
Number of subjects: 0
Study: 31824976

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15754